Research Article

Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy

Takehito Iwase, Hirotaka Yokouchi, Masayasu Kitahashi, Mariko Kubota-Taniai, Takayuki Baba, and Shuichi Yamamoto

Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan

Correspondence should be addressed to Hirotaka Yokouchi; yokouchi123@peace.ocn.ne.jp

Received 22 March 2020; Revised 2 July 2020; Accepted 27 July 2020; Published 18 August 2020

Academic Editor: Mitsuru Nakazawa

Copyright © 2020 Takehito Iwase et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The purpose of this study was to evaluate the long-term effects of half-time photodynamic therapy (PDT) on the retinal sensitivity in eyes with chronic central serous chorioretinopathy (CSC). Twenty-two eyes of 22 patients with chronic CSC were studied. PDT was applied with full-dose verteporfin and half-time laser duration. The best-corrected visual acuity (BCVA) and retinal sensitivity in the central 2 and 10 degrees were evaluated at the baseline, and at 12 and 24 months after the half-time PDT. The retinal sensitivity was determined by Macular Integrity Assessment microperimetry (MAIA, Centervue, Padova, Italy). The results showed that the mean retinal sensitivities in the central 2 and 10 degrees were significantly improved at 12 months (25.6 ± 2.79 dB, median; 26.11 dB, 25.6 ± 2.25 dB, median; 25.65 dB, respectively; P < 0.001) and at 24 months (26.3 ± 2.62 dB, median; 27.38 dB, 26.6 ± 2.21 dB, median; 27.45 dB, respectively; P < 0.001) after the treatment compared to that at the baseline. The BCVA was also significantly improved from 0.18 ± 0.19 median; 0.15 logarithm of the minimum angle of resolution (logMAR) units at the baseline to 0.07 ± 0.15 median; 0 logMAR units at 12 months (P < 0.001) and to 0.049 ± 0.16 median; -0.039 logMAR units at 24 months (P < 0.001).

We conclude that half-time PDT results in a significant improvement of the mean central retinal sensitivity for at least 24 months in eyes with chronic CSC. Thus, half-time PDT is beneficial in resolving chronic CSC for a relatively long period.

1. Introduction

Central serous chorioretinopathy (CSC) is characterized by a serous retinal detachment in the macular area. The serous retinal detachment (SRD) is caused by a leakage of fluid from the choroid into the subretinal space by a breakdown of the barrier in the retinal pigment epithelium (RPE) [1]. Indocyanine green angiographic images have shown hyperpermeable choroidal vessels [2], and enhanced-depth imaging optical coherence tomographic (EDI-OCT) images have shown a thickened choroid in eyes with CSC [3]. Acute CSC is often a self-limiting disorder, and the visual acuity recovers after the resolution of the SRD. However, some patients have a recurrence and the eye is then defined as having chronic CSC. If left untreated, chronic CSC can progress to diffuse RPE atrophy [4].

There are several successful treatments for CSC such as focal laser photocoagulation [5, 6], and it has been recently shown that photodynamic therapy (PDT) with verteporfin is a very effective treatment [7, 8]. Hyperperfusion and hyperpermeability of the choriocapillaris appear to be the primary alterations in the early stage of acute and chronic CSC. Laser photocoagulation can stop the leakage of fluid from the RPE by coagulating the leakage points, but it is not specific enough in resolving the fundamental choroidal vascular problem [9].

It is believed that the mechanism for resolving the SRD by PDT with verteporfin might be that the PDT induces vascular endothelial damage and thrombus formation due to a short-term choriocapillaris occlusion and a long-term choroidal vascular remodeling. These alterations lead to a normalization of the dilated choroidal vessels and a reduction in choroidal congestion, vascular hyperpermeability, and
extravascular leakage. As a result, the SRD would improve in the eyes with CSC [7–9].

PDT treatment for chronic CSC has been reported to result in positive visual outcomes in most studies [7–9]. However, it has been reported that conventional PDT occasionally had serious side-effects such as RPE atrophy, choroidal ischemia, and secondary choroidal neovascularization [7, 9]. To mitigate these adverse side effects, several studies have reported using a safety-enhanced PDT with one-half of the conventional dose of verteporfin (3 mg/m²) [10–12] or with reduced fluence of 25 J/cm² for 83 seconds, i.e., 300 mW/cm², in eyes with chronic CSC [13, 14].

In addition, it has been reported that PDT with half the usual exposure time was reported to be a helpful treatment for chronic CSC [15, 16]. These modified PDT applications had reduced photodynamic effects on chronic CSC with fewer complications and side effects compared to conventional PDT.

Although visual acuity is an important parameter of the overall visual function, it tests only the foveal function, and some patients with chronic CSC with good visual acuity might have poor contrast sensitivity, color discrimination, dark-adaptation, and macular sensitivity [17–20]. Some studies have shown that patients with resolved CSC and good visual acuity have significantly lower central retinal sensitivity [21, 22]. Thus, the assessment of the BCVA alone may give false information of the overall visual functioning of an individual.

The Macular Integrity Assessment Micropereimeter (MAIA, Centervue, Padova, Italy) is a relatively new instrument that can obtain digital fundus images with automated microperimetry. Improvements of the retinal sensitivity around the macular before and after half-dose PDT, [12, 23] half-fluence PDT, [14, 24], and half-time PDT [16] have been recently reported for eyes with chronic CSC. Senturk et al. reported that the retinal sensitivity was improved 6 months after half-dose PDT [12], and Fujita et al. similarly reported that the retinal sensitivity was improved 12 months after half-dose PDT [23]. Casalino et al. reported that retinal sensitivity was improved 2 months after half-fluence PDT [24], and Reibaldi et al. reported that retinal sensitivity was improved 12 months after half-fluence PDT [14]. Muslubas et al. reported that retinal sensitivity was improved 3 months after half-time PDT [16]. These findings indicated that PDT can have good results for at least 12 months. Although Sheptulin et al. used half-time PDT on a large cohort of chronic CSC eyes, they evaluated the retinal function only by the BCVA [15]. To the best of our knowledge, there have not been any studies that determined the changes of retinal sensitivity and BCVA at 24 months after half-time PDT.

Thus, the purpose of this study was to determine the effects of half-time PDT on the macular sensitivity and BCVA after 24 months in eyes with chronic CSC.

2. Materials and Methods

2.1. Study Participants and Statement of Ethics. This was a retrospective, observational case series of 22 eyes (right 10 and left 12) from 22 patients with chronic CSC of ≥6 months duration. The procedures used in this study were approved by the Institutional Review Board of Chiba University Graduate School of Medicine (No.2601). A signed written informed consent was obtained from all patients. The procedures of this study followed the tenets of the Declaration of Helsinki.

The inclusion criteria were the presence of SRD involving the fovea in the optical coherence tomographic (OCT) images of at least 6 months duration. All patients had the following characteristics: axial length between 21.0 mm and 26.5 mm or refractive error between -6 and +6 diopters; intraocular pressure between 10 to 20 mmHg; and no uveitis and glaucoma. Patients who had evidence of choroidal neovascularization, polypoidal choroidal vasculopathy, or other maculopathies documented by fluorescein angiography (FA) or indocyanine green angiography (ICGA) were excluded. Patients who had undergone PDT two or more times were also excluded when they had a recurrence of a SRD.

A chronic CSC refers to a prolonged absence of a spontaneous resolution of the SRD involving the macula and is associated with the idiopathic leakage from the RPE during fluorescein angiography. ICGA was used to confirm the presence of choroidal vascular hyperpermeability, to determine the size of the hyperpermeability to guide the PDT if indicated, and to exclude the presence of polypoidal choroidal vasculopathy or choroidal neovascularization. A history of the medical and ocular disease was obtained from the medical records of each patient, and a complete ophthalmic examination including determination of the best-corrected visual acuity (BCVA), slit-lamp biomicroscopy, OCT, FA, and ICGA was performed. All OCT images were obtained with the Heidelberg Spectralis OCT instrument (Heidelberg Engineering, Heidelberg, Germany) at the baseline, and at 12 and 24 months after the treatment. The measurements from the outer border of retinal pigment epithelium (RPE) to the inner border of the sclera were used to determine the subfoveal choroidal thickness (CT) by using the enhanced depth imaging (EDI) algorithm.

2.2. Modified PDT Protocol for Chronic CSC. A modified PDT protocol for chronic CSC was used. The patients received an intravenous injection of verteporfin (Visudyne; Novartis Pharma, Tokyo, Japan) of 6 mg/m² body surface area. Fifteen minutes later, the eye was irradiated by a diode laser (689 nm) for 42 seconds with a fluence of 50 J/cm² using the Visulys PDT system 690S (Carl Zeiss Mediac AG, Jena, Germany). The exposure time was set at one-half of the standard setting to reduce the total energy to one-half of that of standard fluence-PDT. The area of the laser spot was determined by the size of the lesion in the ICGA images, and the size covered the entire choroidal vascular hyperpermeability lesion plus a margin of 1000 μm. All PDT treatments were performed by the same medical retina specialist (HY). After the treatment, the patients were instructed to wear protective spectacles and to avoid strong light for 48 h.

2.3. Macular Integrity Assessment Micropereimetry (MAIA). An assessment of the location and stability of the fixation was determined by Macular Integrity Assessment microperimetry (MAIA, Centervue, Padova, Italy). The threshold macular sensitivity and fixation stability were determined with the MAIA device. MAIA is a nonmydriatic, near-infrared, line-scanning,
laser ophthalmoscope, which incorporates a high-frequency eye tracker and an automated threshold fundus perimeter. The automated eye tracker locks onto the entire fundus image and records fixation changes 25 times/sec during the testing. The software identifies the preferred retinal locus that identifies the patient’s preferred fixation site. An automated retinal sensitivity program using a Goldmann III stimuli size on a grid of 37 stimuli covering an area of 10 degrees centered on the patient’s preferred retinal location.

2.4. Statistical Analyses. Statistical analyses were performed with the SPSS software for Microsoft Windows (SPSS V.26, IBM Japan, Tokyo). Wilcoxon signed-rank tests were used to determine whether retinal sensitivity, the BCVA, and the CT at each posttreatment time were significantly different from that at baseline. Spearman’s rank correlation test was performed to determine the significance of the correlations between the BCVA and retinal sensitivity at the baseline, 12 and 24 months after treatment and between the changes in the BCVA (logMAR units) and the retinal sensitivity from the baseline to 24 months after the treatment. A $P < 0.05$ was taken to be statistically significant.

3. Results

All 22 patients were Japanese (18 men, 4 women), and their mean age was $57.5 \pm 11.0$ years with a range of 32 to 73 years. The demographics of the patients are shown in Table 1.

| Number of eyes | 22 |
| Mean ± SD age (years) | 57.5 ± 11.0 |
| Sex | Male 18; female 4 |
| Mean ± SD spot size diameter (μm) | 4148 ± 984 (median; 4250) |
| Mean ± SD baseline BCVA (logMAR) | 0.18 ± 0.19 (median; 0.15) |
| Mean ± SD baseline retinal sensitivity 2 degrees (dB) | 19.28 ± 3.93 (median; 19.34) |
| Mean ± SD baseline retinal sensitivity 10 degrees (dB) | 20.97 ± 2.92 (median; 20.9) |
| Mean ± SD baseline choroidal thickness (μm) | 400.9 ± 92.1 (median; 409) |

SD: standard deviation; BCVA: best-corrected visual acuity; logMAR: logarithm of the minimum angle of resolution.

As described, the mean retinal sensitivities in the central 10 degrees were also significantly improved to $25.69 \pm 2.25$ dB (median; $25.65$ dB) at 12 months and to $26.66 \pm 2.21$ dB (median; $27.45$ dB) at 24 months ($P < 0.01$). The mean retinal sensitivity in the central 2 degrees was $26.60 \pm 2.79$ dB (median; $26.61$ dB) at 12 months which was not significantly different from $26.32 \pm 2.62$ dB (median; $27.38$ dB) at 24 months ($P = 0.13$).

The mean BCVA at the baseline was $0.18 \pm 0.19$ (median; 0.15) logMAR units, and it significantly improved to $0.065 \pm 0.14$ (median; 0) logMAR units at 12 months ($P < 0.001$) and to $0.049 \pm 0.15$ (median; 0.039) logMAR units at 24 months ($P < 0.001$) after the half-time PDT. The BCVA at 12 months was not significantly different from that at 24 months ($P = 0.21$) after the half-time PDT (Figure 4).

The BCVA improved in 13 patients (59%), had not changed significantly in 8 patients (36%), and worsened in 1 patient (5%) at 12 months after the treatment. In 4 patients (18%), the BCVA improved at 24 months compared to that at 12 months and the BCVA worsened in 2 patients (9%) at 24 months compared to that at 12 months. In 16 patients (73%), the BCVA did not change at 24 months compared to that at 12 months. In 1 patient (5%), the BCVA worsened at 24 months compared to that at the baseline. In 15 patients (68%), the BCVA improved significantly at 24 months compared to the baseline. In 6 patients (27%), the BCVA did not change significantly at 24 months compared to baseline.
The mean choroidal thickness (CT) at the baseline was 400.9 ± 92.2 μm (median; 409 μm), and it decreased significantly to 299.5 ± 98.0 μm (median; 297 μm) at 12 months (P < 0.001) and 305.8 ± 109.3 μm (median; 288.5 μm) at 24 months (P < 0.001) after the half-time PDT (Figure 5). The CT had decreased in 20 patients (91%) and had not decreased in 2 patients (9%) at 12 months and 24 months after the treatment.

Figure 1: Findings in patients with chronic central serious chorioretinopathy (CSC) treated by half-time photodynamic therapy (PDT). Microperimetric images and optical coherence tomographic images of the left eye of a 43-year-old man with chronic CSC treated with half-time PDT at the baseline (a) and at 12 months (b) and 24 months (c) after treatment. His baseline decimal best-corrected visual acuity (BCVA) was 0.9, and the mean retinal sensitivity was 19.7 dB. After the half-time PDT, the symptoms were improved, and the serous retinal detachment was resolved. At 12 months after the treatment, the decimal BCVA was 1.2 and the retinal sensitivity was 26.3 dB. At 24 months, his BCVA was 1.2 and the retinal sensitivity was 27.6 dB.
The mean retinal thickness at 12 months and 24 months after the half-time PDT were $167.8 \pm 33.1 \mu m$ (median; 174 $\mu m$) and $166.5 \pm 37.6 \mu m$ (median; 169 $\mu m$).

There was no significant correlation between the retinal thickness and retinal sensitivity after the half-time reduced-fluence therapy. However, as reported, we had divided our
patients into a continuous group, a fragmented group, and an absent group based on an earlier study on the integrity of the ellipsoid zone (EZ) at 12 months posttreatment [25]. There were 13 of our cases in the continuous group, 8 cases in the fragmented group, and 1 case in the absent group. The retinal sensitivity was significantly higher in the continuous group than the other two groups. \( P < 0.001 \) Mann-Whitney \( U \) test.

The correlations between the BCVA and the retinal sensitivity in the central 2 and 10 degrees were not significant.
the baseline ($P = 0.30, P = 0.15$; Table 3). On the other hand, there were significant negative correlations between the BCVA and the retinal sensitivity of the central 2 and 10 degrees at 12 months ($r = -0.623, P < 0.01$ and $r = -0.574, P < 0.01$; Table 3) and at 24 months ($r = -0.620, P < 0.01$ and $r = -0.574, P < 0.01$; Table 3). The changes in the BCVA from the baseline was not significantly correlated with the changes in retinal sensitivity in central 2 and 10 degrees at 12 months ($P = 0.15, P = 0.07$; Table 4) and at 24 months ($P = 0.18, P = 0.11$; Table 4).

### Table 3: Correlation between best-corrected visual acuity and retinal sensitivity.

|                | Baseline | 12 months | 24 months |
|----------------|----------|-----------|-----------|
| 2 degrees      | -0.226 ($P = 0.3$) | -0.623 ($P < 0.01$) | -0.62 ($P < 0.01$) |
| 10 degrees     | -0.313 ($P = 0.15$) | -0.574 ($P < 0.01$) | -0.568 ($P < 0.01$) |

BCVA: best-corrected visual acuity; logMAR: logarithm of the minimum angle of resolution.

### Table 4: Correlation between the changes in BCVA and retinal sensitivity.

|                | From 12 months to baseline | From 24 months to baseline |
|----------------|-----------------------------|---------------------------|
| 2 degrees      | -0.313 ($P = 0.15$)         | -0.29 ($P = 0.18$)        |
| 10 degrees     | -0.389 ($P = 0.07$)         | -0.347 ($P = 0.11$)       |

BCVA: best-corrected visual acuity; logMAR: logarithm of the minimum angle of resolution.

### 4. Discussion

Our results showed that the mean retinal sensitivity in the central 2 and 10 degrees in eyes with chronic CSC was significantly better after half-time PDT at both 12 and 24 months than that at the baseline. The mean BCVA was also significantly better at 12 and 24 months than that at the baseline. These findings indicated that half-time PDT is effective in improving BCVA and retinal sensitivity in the macular region for at least 24 months. The CT was significantly thinner at 12 and 24 months than at the baseline. These results showed that the effect of this treatment on CT lasted for at least 24 months. Earlier studies had shown a decrease of the choroidal thickness after 1 week of PDT for CSC [26]. Unfortunately, we do not have any data of the retinal sensitivity at 1 week, so we cannot discuss about the thickness of the choroid and improved retinal sensitivity at an earlier period after PDT.

But, in this study, we mainly focused on the long-term course of PDT treatment for CSC, and even at 12 and 24 months after the PDT, the choroid was still thinner than that at the baseline. Thus, we believe that the effects of PDT had lasted not only in the long term, but also in the short term.

In all patients, the retinal sensitivity had improved at 24 months compared to that at baseline, but in 5 patients (23%), the retinal sensitivity was reduced at 24 months compared to retinal sensitivity at 12 months. In one of the 5 patients, the retinal sensitivity improved at 12 months and then decreased at 24 months. In 4 of 5 patients, the retinal sensitivity decreased once at 12 months and then increased at 24 months. The reason for these findings may be because there was a recurrence of the CSC which happened between the 6 and 12 months examination periods.

In the central 10 degrees, the mean retinal sensitivity was also significantly better at 24 months than at 12 months even though the BCVA at 24 months was not significantly different than the BCVA at 12 months. Even when the visual acuity reached a plateau at 12 months, some functions of the retina such as the retinal sensitivity can still improve until 24 months.

There have been many studies on the BCVA after half-time PDT treatments for chronic CSC with a posttreatment of more than two years [15, 27–33]. Although there were several studies that followed the retinal sensitivity for a long period [12, 14, 16, 23, 34–38], most of the follow-up period was at most one year. On the other hand, our experimental period extended for 24 months which provided information on the long-term effects of half-time PDT.

The different methods of using PDT for CSC include conventional, half-dose [12, 23], half-energy [14, 24], and half-time PDT [15, 16]. Previous reports showed that both these half-fluence PDT and conventional PDT were effective but half-fluence PDT had fewer side effects than conventional PDT. Senturk et al. and Fujita et al. evaluated the BCVA and retinal sensitivity before and after half-dose PDT for CSC at 6 and 12 months after the treatment [12, 23]. Reibaldi et al. and Hagen et al. reported that the BCVA and retinal sensitivity were improved at 12 months after half-fluence (half-energy) PDT [13, 37]. Sheptulin et al. reported that half-time PDT was effective in significantly improving the BCVA after 12 months [15]. Muslubas et al. also reported the improvement in retinal sensitivity 3 months after half-time PDT [16]. In these studies, the short-term and intermediate-term effects of half-dose PDT, half-fluence PDT, and half-time PDT were determined on the retinal sensitivity in eyes with CSC. To the best of our knowledge, our retinal sensitivity findings at 24 months are the first long-term findings.

The mean diameter of the laser spot in our study was $4148 \pm 984 \mu m$ while that of Senturk et al. was $2500 \pm 455 \mu m$, Fujita et al. was $4371.4 \pm 910.1 \mu m$, and Hagen et al. was $1700 \pm 455 \mu m$. The exact calculation of the spot size reduced the risk of collateral damage such as choroidal ischemia, retinal atrophy, or development of choroidal neovascular [39]. Our spot size was larger than that of the other studies but the retinal sensitivity significantly improved at 1 month after the treatment although the retinal sensitivity in 3 patients (13.6%) worsened, 16 patients (72.7%) had an improvement, and the sensitivity of 3 patients was not recorded. At 12 months, the retinal sensitivity in the central 10 degrees significantly improved in 21 patients (95%). In all patients, the retinal sensitivity in the central 10 degrees improved at 24 months compared to that at the baseline. Eventually, the retinal sensitivity improved and there were no complications. Our average spot size was larger than that of earlier studies but there were no complications and the effect was maintained for a relatively long time.

In some patients with relatively good vision before treatment, the retinal sensitivity improved slowly and gradually.
for 24 months after the treatment. The reason for this is that the visual acuity reflects only the function of the central fovea, and the retinal sensitivity represents the status of a larger area of the foveal area. Thus, it is important to measure the retinal sensitivity in patients with chronic CSC and to evaluate the visual function in greater detail because the visual acuity does not necessarily reflect the overall visual function.

Many studies have examined the relationship between the BCVA and macular retinal sensitivity. Chung et al. and Kim et al. reported that the BCVA was significantly correlated with the mean retinal sensitivity around the macula in eyes with a resolved CSC [40, 41]. Chiba et al. showed that the BCVA was significantly correlated with the foveal sensitivity in macular thickening disorders [42]. Sugiura et al. also reported similar results between the BCVA and macular retinal sensitivity, but this significant relationship was not observed when the retinal sensitivity was calculated from a wider retinal area in eyes with chronic CSC [43].

There was a significant correlation between the BCVA and retinal sensitivity in our patients at 12 and 24 months, but they were not significantly correlated at the baseline. The reason why this lack of correlation is at the baseline might be because of the presence of the SRD. The changes in the BCVA were not significantly correlated with the changes in retinal sensitivity before and after the half-time PDT (Table 4). The reason for this discrepancy might be that there were many cases in which the visual acuity did not change significantly because they already had good visual acuity before treatment. Thus, we believe that it might be a ceiling effect. On the other hand, even at 24 months, the retinal sensitivity had increased more than at 12 months. From these results, we conclude that half-time PDT is a very useful method to treat patients with chronic CSC even those with relatively good visual acuity.

There was no significant difference between the retinal sensitivity at 2 and 10 degrees before the treatment but there was a tendency that retinal sensitivity at 2 degrees was lower than the retinal sensitivity at 10 degrees. \( P = 0.057 \) (Mann-Whitney U test). The reason why there was this difference might be the effects of the SRD. It has been recently reported that there was a significant correlation between the retinal sensitivity and the SRD height [26]. On the other hand, there was no significant difference between retinal sensitivity at 2 and 10 degrees at 12 months after the treatment because of the absence of the SRD. \( P = 0.98 \) (Mann-Whitney U test).

There was no significant correlation between the retinal thickness and retinal sensitivity after the half-time reduced-fluence therapy. However, as reported, we had divided our patients into a continuous group, a fragmented group, and an absent group based on an earlier study on the integrity of the ellipsoid zone (EZ) at 12 months posttreatment [25]. There were 13 of our cases in the continuous group, 8 cases in the fragmented group, and 1 case in the absent group. The retinal sensitivity was significantly higher in the continuous group than the other two groups \( P = 0.01 \) (Mann-Whitney U test). The improvements of the retinal sensitivity were associated with an improvement in the integrity of the EZ [40, 44]. We were not able to detect the IZ consistently in all our patients posttreatment, and thus cannot determine if there was a change in the IZ post-treatment. Before the treatment, we could not see either the EZ or IZ because the retina was completely detached at the macular area by the existence of SRD.

As we mentioned, there was no specific relationship between the retinal structure and retinal sensitivity before treatment. We believe that the lack of correlation between visual acuity and retinal sensitivity means that the SRD has only a slight effect on the BCVA. We believe that the retinal sensitivity might be a method that can detect changes in the visual function that cannot be detected by the BCVA.

Our study has several limitations. First, the sample size was small, and this was a retrospective study without a control group. The lack of a control group may limit generalizations and definitive comparisons of half-time PDT with other treatment methods. Further prospective studies with a control group or other modified treatment groups, such as half-dose or half-fluence PDT in a larger sample, will be needed to determine the efficacy of half-time PDT on the retinal sensitivity in eyes with CSC. A second limitation was that the significant increase in the mean central retinal sensitivity over 24 months in eyes with chronic CSC might be a learning effect or test-retest variations [45, 46]. This can be best examined by having a control group but then ethical problems will arise.

In conclusion, the retinal sensitivity and BCVA improved and were maintained for at least 24 months after half-time PDT in eyes with chronic CSC. Our findings indicate that it is important to examine the retinal sensitivity when evaluating the effect of half-time PDT in eyes with chronic CSC. Although further evaluations with a larger sample size are needed, our results showed that half-time PDT was beneficial for resolving chronic CSC for at least 24 months.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no competing interests.

Authors’ Contributions

HY and TI designed this study; HY and TI collected the data; HY and TI analysed the data; TB and SY drafted the article. HY, MK, MK-T, TB, and SY reviewed the manuscript.

Acknowledgments

The authors thank Professor Emeritus Duco Hamasaki of the Bascom Palmer Eye Institute of the University of Miami for his critical discussion and final manuscript revision.

References

[1] J. Donald and M. Gass, "Pathogenesis of disciform detachment of the neuroepithelium," American Journal of Ophthalmology, vol. 63, no. 3, pp. 573/1–585/13, 1967.
[2] C. Prunte and J. Flammer, “Choroidal capillary and venous congestion in central serous chorioretinopathy,” *American Journal of Ophthalmology*, vol. 121, no. 1, pp. 26–34, 1996.

[3] Y. Imamura, T. Fujiwara, R. Margolis, and R. F. Spaide, “Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy,” *Retina*, vol. 29, no. 10, pp. 1469–1473, 2009.

[4] R. H. Loo, I. U. Scott, H. W. Flynn Jr. et al., “Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy,” *Retina*, vol. 22, no. 1, pp. 19–24, 2002.

[5] D. M. Robertson and D. Ilstrup, “Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy,” *American Journal of Ophthalmology*, vol. 95, no. 4, pp. 457–466, 1983.

[6] E. Burumcek, A. Mudun, S. Karacorlu, and M. O. Arslan, “Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up,” *Ophthalmology*, vol. 104, no. 4, pp. 616–622, 1997.

[7] F. C. Piccolino, C. Eandi, L. Ventre, R. Rigault De La Longrais, and F. Grignolino, “Photodynamic therapy for chronic central serous chorioretinopathy,” *Retina*, vol. 23, no. 6, pp. 752–763, 2003.

[8] L. A. Yannuzzi, J. S. Slakter, N. E. Gross et al., “Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous CHIROIDETINOPATHY,” *Retina*, vol. 32, Supplement 1, pp. 288–298, 2012.

[9] W. M. Chan, D. S. Lam, T. Y. Lai, B. S. Tam, D. T. Liu, and C. K. Chan, “Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level,” *The British Journal of Ophthalmology*, vol. 87, no. 12, pp. 1453–1458, 2003.

[10] W. M. Chan, T. Y. Lai, R. Y. K. Lai, D. T. L. Liu, and D. S. C. Lam, “Half-dose verteporfin photodynamic therapy for acute central serous Chorioretinopathy,” *American Journal of Ophthalmology*, vol. 115, no. 10, pp. 1756–1765, 2008.

[11] J. W. Lim, S. W. Kang, Y. T. Kim, S. E. Chung, and S. W. Lee, “Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy,” *The British Journal of Ophthalmology*, vol. 95, no. 4, pp. 514–517, 2011.

[12] F. Senturk, M. Karacorlu, H. Ozdemir, S. A. Karacorlu, and O. Uysal, “Microperimetric changes after photodynamic therapy for central serous chorioretinopathy,” *American Journal of Ophthalmology*, vol. 151, no. 2, pp. 303–309.e1, 2011.

[13] M. Reibaldi, N. Cardascia, A. Longo et al., “Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial,” *American Journal of Ophthalmology*, vol. 149, no. 2, pp. 307–315.e2, 2010.

[14] M. Reibaldi, F. Boscia, T. Avitabile et al., “Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy,” *American Journal of Ophthalmology*, vol. 151, no. 6, pp. 953–960.e2, 2011.

[15] V. Sheputin, K. Purtikhvanidze, and J. Roider, “Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy,” *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 256, no. 11, pp. 2027–2034, 2018.

[16] I. S. Muslubas, M. G. Ersoz, M. Hocaoglu, S. Arf, and M. Karacorlu, “Morphological and functional changes immediately after half-time photodynamic therapy in patients with central serous chorioretinopathy,” *Ophthalmic Surgery, Lasers & Imaging Retina*, vol. 49, no. 12, pp. 932–940, 2018.

[17] J. C. Folk, H. S. Thompson, D. P. Han, and C. K. Brown, “Visual function abnormalities in central serous retinopathy,” *Archives of Ophthalmology*, vol. 102, no. 9, pp. 1299–1302, 1984.

[18] E. L. Chuang, D. M. Sharp, F. W. Fitzke, C. M. Kemp, A. L. Holden, and A. C. Bird, “Retinal dysfunction in central serous retinopathy,” *Eye (London)*, vol. 1, no. 1, pp. 120–125, 1987.

[19] M. F. Marmor and F. Tan, “Central serous chorioretinopathy: bilateral multifocal electoretinographic abnormalities,” *Archives of Ophthalmology*, vol. 117, no. 2, pp. 184–188, 1999.

[20] T. H. Maaranen, K. T. Tuppurainen, and M. I. Mantyjarvi, “Color vision defects after central serous chorioretinopathy,” *Retina*, vol. 20, no. 6, pp. 633–637, 2000.

[21] H. Ozdemir, F. Senturk, M. Karacorlu, S. Arf Karacorlu, and O. Uysal, “Macular sensitivity in eyes with central serous chorioretinopathy,” *European Journal of Ophthalmology*, vol. 18, no. 5, pp. 799–804, 2018.

[22] Y. Ojima, A. Tsujikawa, M. Hangai et al., “Retinal sensitivity measured with the micro perimeter 1 after resolution of central serous chorioretinopathy,” *American Journal of Ophthalmology*, vol. 146, no. 1, pp. 77–84.e1, 2008.

[23] K. Fujita, K. Shinoda, C. S. Matsumoto et al., “Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy,” *Clinical Ophthalmology*, vol. 6, pp. 1681–1687, 2012.

[24] G. Casalino, C. Del’Turco, F. Corvi, O. Rafaeli, F. Bandello, and G. Querques, “Short-term retinal sensitivity and metamorphopsia changes following half-fluence photodynamic therapy in central serous chorioretinopathy,” *Ophthalmic Research*, vol. 56, no. 1, pp. 23–29, 2016.

[25] K. Fujita, K. Shinoda, Y. Imamura et al., “Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy,” *American Journal of Ophthalmology*, vol. 154, no. 3, pp. 579–585, 2012.

[26] I. Maruko, T. Iida, Y. Sugano, A. Ojima, M. Ogasawara, and R. F. Spaide, “Subfoveal choroidal thickness after treatment of central serous chorioretinopathy,” *Ophthalmology*, vol. 117, no. 9, pp. 1792–1799, 2010.

[27] H. Vasconcelos, I. Marques, A. R. Santos et al., “Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy,” *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 251, no. 7, pp. 1697–1705, 2013.

[28] F. Haga, R. Maruko, C. Sato, K. Kataoka, Y. Ito, and H. Terasaki, “Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: a 3-year follow-up study,” *PloS One*, vol. 12, no. 7, p. e0181479, 2017.

[29] B. K. Son, K. Kim, E. S. Kim, and S. Y. Yu, “Long-term outcomes of full-fluence and half-fluence photodynamic therapy for chronic central serous chorioretinopathy,” *Ophthalmologica*, vol. 241, no. 2, pp. 105–115, 2019.

[30] N. A. Dhirani, Y. Yang, and S. Somani, “Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy,” *Clinical Ophthalmology*, vol. 11, pp. 2145–2149, 2017.
[31] E. Leys, S. Tuttle, F. Rasquin, F. Neu, and L. Postelmans, "Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy," *Journal Français d’Ophtalmologie*, vol. 38, no. 8, pp. 709–716, 2015.

[32] C. C. Tseng and S. N. Chen, "Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy," *The British Journal of Ophthalmology*, vol. 99, no. 8, pp. 1070–1077, 2015.

[33] R. M. Silva, J. M. Ruiz-Moreno, F. Gomez-Ulla et al., "Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study," *Retina*, vol. 33, no. 2, pp. 309–315, 2013.

[34] P. Iacono, M. Tedeschi, B. Boccassini, A. Chiaravalloti, M. Varano, and M. Parravano, "Chronic central serous choriotinopathy: early and late morphological and functional changes after verteporfin photodynamic therapy," *Retina*, vol. 39, no. 5, pp. 980–987, 2019.

[35] S. Gulkas and O. Sahin, "Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous choriotinopathy," *European Journal of Ophthalmology*, p. 112067211985887, 2019.

[36] A. Atik, Y. Hu, H. Yu et al., "Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous choriotinopathy," *BMC Ophthalmol*, vol. 17, no. 1, p. 140, 2017.

[37] S. Hagen, S. Ansari-Shahrezaei, E. Smretschnig et al., "The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous choriotinopathy," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 251, no. 4, pp. 1081–1089, 2013.

[38] R. Ehrlich, N. P. Mawer, C. H. Mody, C. S. Brand, and D. Squirrell, "Visual function following photodynamic therapy for central serous choriotinopathy: a comparison of automated macular microperimetry versus best-corrected visual acuity," *Clinical & Experimental Ophthalmology*, vol. 40, no. 1, pp. e32–e39, 2012.

[39] M. Colucciello, "Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy," *Retina*, vol. 26, no. 2, pp. 239–242, 2006.

[40] H. W. Chung, C. M. Yun, J. T. Kim, S. W. Kim, J. Oh, and K. Huh, "Retinal sensitivity assessed by microperimetry and corresponding retinal structure and thickness in resolved central serous choriotinopathy," *Eye (London, England)*, vol. 28, no. 10, pp. 1223–1230, 2014.

[41] S. W. Kim, J. Oh, and K. Huh, "Correlations among various functional and morphological tests in resolved central serous choriotinopathy," *The British Journal of Ophthalmology*, vol. 96, no. 3, pp. 350–355, 2012.

[42] N. Chiba, M. Imasawa, T. Goto, M. Imai, and H. Iijima, "Foveal sensitivity and visual acuity in macular thickening disorders," *Japanese Journal of Ophthalmology*, vol. 56, no. 4, pp. 375–379, 2012.

[43] A. Sugiura, R. Fujino, N. Takemiya et al., "The association between visual function and retinal structure in chronic central serous choriotinopathy," *Scientific Reports*, vol. 7, no. 1, p. 16288, 2017.

[44] A. Fujita, Y. Aoyama, S. Tsuneyoshi et al., "Association between visual function and the integrity of residual ellipsoid zone in resolved central serous choriotinopathy," *Scientific Reports*, vol. 9, no. 1, p. 12433, 2019.